RT-PCR

A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.

The university's researchers have developed a laboratory test that measures the body's response to infection in the blood, and can distinguish between bacterial and viral meningitis.  

This Week in PNAS

In PNAS this week: genetic diversity of MERS in African camels, centromere evolution in Cryptococcus, and more.

Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.  

HER3 mRNA expression analysis can predict colorectal cancer patients with wild-type RAS tumors who will respond to panitumumab, US and UK researchers reported.

The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.

The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.

Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.

This Week in PLOS

In PLOS this week: gene-environment interactions affecting BMI, transposon mutagenesis study of UTI-linked bacteria, and more.

The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.

Pages

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.